The Global Stem Cell Banking Market
, by Source Type (Cord Blood and Cord Tissue), by Service Type (Collection and Transportation, Processing, Analysis, and Storage), by Application (Leukemia, Diabetes, Lymphoma, Cerebral Palsy, Thalassemia, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa
) was valued at US$ 1,634.7
million in 2016 and is projected to exhibit a CAGR of 18.9%
over the forecast period (2017–2025).
The stem cell banking market is expected to gain significant traction, owing to increasing awareness regarding use of cord blood and cord tissue stem cells in therapeutics, coupled with increasing application of stem cells in the treatment of autism, lymphoma, anemia and others.
Request for Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1354
Increasing survival rate of patients post stem cell transplant is expected to augment growth the stem cell banking market Increasing use and applications of stem cells for treatment of patients diagnosed with blood-related cancers is a major factor propelling growth of the stem cell banking market. According to the Leukemia and Lymphoma Society, 2017, an estimated 172,910 people in the U.S. were diagnosed with leukemia, lymphoma or myeloma in 2017 thus, leading to increasing adoption of stem cells for efficient treatment. Furthermore, according to the research study by Journal of Clinical Oncology, 2013, stem cell transplants for elderly patients with blood cancers are safe and effective and showed better outcome with reduction in post-transplant complications such as graft-versus-host disease by 37%. The study also stated that the survival chance after a year of stem cell transplant was around 42% and the overall survival rate was also estimated to be 55%.
Moreover, launch of innovative products and treatment therapies such as allogenic cord-blood derived hematopoietic stem cell therapy is another factor bolstering the market growth. For instance, in 2011, the FDA approved Hemacord—the first FDA-licensed hematopoietic progenitor cells-cord (HPC-C) cell therapy manufactured by New York Blood Center, Inc. Hemacord uses cord blood stem cells to treat certain disorders of the hematopoietic or blood forming system. Also, in 2014, Hemacord was awarded as Best Biotechnology Product Award by Prix Galien USA.
Apply Promo Code “STAYHOME” and Get Instant Discount of USD 1000
If you purchase the report this year:
Flat 20% instant discount
25% discount on 2nd report
15 % free customization
Buy This Complete A Business Report @: https://www.coherentmarketinsights.com/insight/buy-now/1354
Manufacturers are focusing on regenerative medicine research for harnessing the potential of umbilical cord blood stem cells for use in treating diseases and conditions that have no known cure. Manufacturers are also collaborating with academic researchers to help expand the potential uses of newborn stem cell therapies that may be available to patients and their families.
For instance, in February 2018, the Institute of Integrative Biology collaborated with Anika Therapeutics, Inc., to develop an injectable mesenchymal stem cell (MSC) therapy for the treatment of osteoarthritis. Moreover, in 2016, Axiogenesis AG and Metrion Biosciences Ltd., collaborated to validate, optimize, and commercialize induced pluripotent stem cell-derived cells and tissues to speed up research in drug discovery. Also, in 2015, MAG Pharmaceuticals, Inc. acquired Cord Blood Registry (CBR)—an umbilical cord blood stem cell collection and storage company—for US$ 700 million, to expand and diversify its maternal health business.
Some of the major players operating in the global stem cell banking market are Stem Cyte, Inc., Cryo-cell International, ViaCord, Cord Blood Registry, SmartCells, Inc., LifeCell International Pvt. Ltd., Cryoviva Biotech Pvt. Ltd., Cryo Stemcell, Reliance Life Sciences, and Transcell Biolife Pvt. Ltd.
Direct Line: +1-206-701-6702 (US)